An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.

Date publication

juin 2016

Journal

BMJ open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent , Dr DABAKUYO-YONLI Sandrine , Pr HILLON Patrick , Dr JOUVE Jean-Louis , Dr MINELLO Anne

Tous les auteurs :
Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27342239

Résumé

The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD).

Mots clés

Health-related Quality of Life, longitudinal analysis, oncology clinical trial, phase I, time to deterioration

Référence

BMJ Open. 2016 Jun;6(6):e010696